Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready?
Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype with poor prognosis that has historically relied on chemotherapy due to a lack of targeted treatment options. In this debate, experts examine whether emerging data on antibody-drug conjugates (ADCs), including sacituzumab govitecan, support a shift away from a chemotherapy-first approach and how these agents can be effectively integrated into clinical practice.
Round 1
This debate examines whether the urgency of treating mTNBC justifies moving beyond a chemotherapy-first approach, with proponents arguing that delaying more effective therapies, such as ADCs, may contribute to patient attrition and missed opportunities for benefit. Skeptics emphasize that chemotherapy remains the established first-line standard, citing concerns about ADC toxicity, limited early-line evidence, and clinician readiness to manage these agents in community practice.
Round 2
This discussion explores whether clinician confidence in managing toxicity is the primary barrier to earlier use of ADCs in mTNBC, with proponents arguing that adverse effects are predictable and manageable with appropriate monitoring, supportive care, and updated guidance. Skeptics counter real-world safety concerns—including serious toxicities, variability in practice of readiness, and limited experience with proactive management—continue to hinder broader adoption in community settings.
Round 3
This debate examines whether ADCs can be considered interchangeable in mTNBC, with one perspective suggesting that shared targets and trial variability may explain perceived differences between agents. The opposing view emphasizes that distinctions in payload, linker technology, safety profiles, and patient-specific factors are clinically meaningful, underscoring the need for careful data interpretation and individualized treatment selection.
© 2026 HMP Global. This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
